Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.50 |
| ▸ | CA9 | Q16790 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8691420 | 0.86 | LMNA (0.56) | LMNACA1CA2CA9CA12 | |
| SCHEMBL31387942 | 0.84 | CYP1A2 (0.47) | LMNACA9CA12NQO2MTNR1A | |
| SCHEMBL6181850 | 0.84 | CYP1A2 (0.47) | LMNACA9CA12NQO2MTNR1A | |
| SCHEMBL9244404 | 0.82 | PTPN11 (0.52) | NQO2MTNR1AMTNR1BCYP1A2CYP2A6 | |
| SCHEMBL1804799 | 0.80 | LMNA (0.58) | LMNACA1CA2CA9CA12 | |
| SCHEMBL3140093 | 0.79 | LMNA (0.68) | LMNACA1CA2CA9CA12 | |
| SCHEMBL1808683 | 0.79 | LMNA (0.56) | LMNACA1CA2CA9CA12 | |
| SCHEMBL6254779 | 0.79 | LMNA (0.56) | LMNACA1CA2CA9CA12 | |
| SCHEMBL1804796 | 0.79 | LMNA (0.56) | LMNACA1CA2CA9CA12 | |
| SCHEMBL1808682 | 0.79 | LMNA (0.56) | LMNACA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| CN-103732589-B | Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor | BRISTOL-MYERS SQUIBB CO. (US) | 2016-03-30 | — | — | CN | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | LMNA 2227/4885CA1 2483/4885CA2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.